Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Oxycodone
Drug ID BADD_D01645
Description Oxycodone is a semisynthetic opioid analgesic derived from thebaine in Germany in 1917.[A178696] It is currently indicated as an immediate release product for moderate to severe pain and as an extended release product for chronic moderate to severe pain requiring continuous opioid analgesics for an extended period.[Label] The first oxycodone containing product, Percodan, was approved by the FDA on April 12, 1950.[L6460]
Indications and Usage Oxycodone is indicated for the treatment of moderate to severe pain.[Label] There is also an extended release formulation indicated for chronic moderate to severe pain requiring continuous opioid analgesics for an extended period.[Label]
Marketing Status approved; illicit; investigational
ATC Code N02AA05
DrugBank ID DB00497
KEGG ID D05312
MeSH ID D010098
PubChem ID 5284603
TTD Drug ID D07WPQ
NDC Product Code 71335-0981; 67651-0304; 67651-0305; 67651-0306; 24510-140; 71335-1080; 0904-6966; 24510-130; 65162-048; 67877-625; 71335-0677; 65162-050; 0904-7180; 65162-047; 72162-1812; 67877-623; 67651-0302; 65162-049; 67651-0303; 65162-051; 24510-110; 24510-115; 71335-1023; 24510-120; 72162-1811
UNII CD35PMG570
Synonyms Oxycodone | Dihydrone | Oxycone | Dihydrohydroxycodeinone | Oxycodeinon | Eucodal | Theocodin | Oxycodone Hydrochloride | Oxycontin | Pancodine | Dinarkon | Oxiconum
Chemical Information
Molecular Formula C18H21NO4
CAS Registry Number 76-42-6
SMILES CN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)OC)O4)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Disease progression08.01.03.038--
Pulmonary function test decreased13.19.01.001--Not Available
Hepatobiliary disease09.01.08.003--Not Available
Large intestinal obstruction07.13.03.0030.000041%
Unevaluable event08.01.03.0510.004338%Not Available
Poor quality sleep19.02.05.005; 17.15.04.002--Not Available
Complex regional pain syndrome12.01.12.004; 17.02.07.0100.000062%Not Available
Tumour invasion16.16.01.008--Not Available
Breakthrough pain16.32.03.016; 08.01.08.0260.000290%Not Available
Skin abrasion12.01.06.010; 23.03.11.018--Not Available
Urethral stenosis20.07.03.003--Not Available
Suicidal behaviour19.12.01.0060.000155%Not Available
Cardiovascular insufficiency02.11.01.011; 24.06.03.005--Not Available
Hyperpathia17.02.07.015--Not Available
Substance abuse19.07.06.0180.000497%Not Available
Sphincter of Oddi dysfunction09.02.02.004; 07.18.02.0020.000021%Not Available
Liver injury12.01.17.012; 09.01.07.022--Not Available
Regurgitation07.01.07.0040.000031%Not Available
Type 1 diabetes mellitus14.06.01.010; 10.04.08.007; 05.06.01.010--Not Available
Brain injury19.07.03.007; 17.11.01.0030.000238%Not Available
Oropharyngeal pain22.12.03.016; 07.05.05.004--
Post procedural constipation07.02.02.016; 12.02.03.014--Not Available
Hypoxic-ischaemic encephalopathy24.04.06.021; 22.02.02.011; 17.13.02.0060.000062%Not Available
Oesophageal motility disorder07.02.03.0060.000052%Not Available
Glassy eyes08.01.03.055; 06.08.03.021--Not Available
Lacrimal structural disorder06.06.04.013--Not Available
Hypothalamic pituitary adrenal axis suppression05.03.04.0070.000031%Not Available
Cardiovascular symptom02.11.04.002; 24.03.02.0250.000151%Not Available
Depersonalisation/derealisation disorder19.14.01.004--Not Available
Confabulation19.10.03.0090.000021%Not Available
The 14th Page    First    Pre   14 15 16    Next   Last    Total 16 Pages